Nektar/BMS’s IL-2 Inhibitor Melanoma Failure Leaves Room For Other Contenders

 
• By Alaric DeArment
  
Generate a summary of this article
Listen to this article
Beta

Nektar is hoping the combination of bempegaldesleukin and Opdivo could have better chances in kidney and bladder cancers, but analysts aren’t sure and see other IL-2 therapeutics as having better prospects.

Cancer-cells-pink-color_1200x675
Nektar and BMS announced the failure of their Phase III melanoma study • Source: Shutterstock

One of the leading contenders to improve on interleukin-2 (IL-2)-based therapy in oncology is down and possibly out as Nektar Therapeutics and Bristol Myers Squibb Company announced the failure of the Phase III PIVOT IO-001 trial of Nektar’s bempegaldesleukin (bempeg) and BMS PD-1 inhibitor Opdivo (nivolumab) in first-line melanoma. But competing IL-2 drugs in development may have a better shot as bempeg itself may yet have potential efficacy in other cancers.

Nektar and BMS said 14 March that the PIVOT study failed to meet its primary endpoints of improving progression-free survival...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D